Sinovac Test Subjects Fall Ill; Tested Negative for Covid-19

Translator:

Editor:

Ricky Mohammad Nugraha

  • Font:
  • Ukuran Font: - +
  • Scientists work in the Merah Putih vaccine research facility of the Bio Farma office in Bandung, Wednesday, August 12, 2020. ANTARA/Dhemas Reviyanto

    Scientists work in the Merah Putih vaccine research facility of the Bio Farma office in Bandung, Wednesday, August 12, 2020. ANTARA/Dhemas Reviyanto

    TEMPO.CO, JakartaSeveral volunteers for Phase 3 or the final stage of the Sinovac Covid-19 vaccine candidate clinical trial in Bandung have reportedly fallen ill. However, none of them tested positive for the coronavirus, with their swab test results coming out negative.

    Eddy Fadlayana, the vaccine test's research team manager from the Faculty of Medicine, Padjadjaran University, said the test subjects did not become sick from the immunization. Some, he said, had underlying diseases. "[Some] had a history of high blood pressure, which then recurred. Some are sick with typhus, rheumatism, ulcers," he said on Monday, October 19.

    He did not say the exact number of volunteers who were sick, but said that there are not many. "Just a few, and none had grave illnesses," he said.

    The sick volunteers, he said, reported their health condition to the research team. Then, they were examined by hospital doctors, and the costs are covered by insurance.

    The medical exam result of the sick subjects are submitted to the Ethics Committee and the research consultant team for audit. Eddy said that there have been no other reports of illnesses after the first finding in September.

    To date, clinical trials are still ongoing as scheduled with immunization carried out every Friday. All 1,620 volunteers had their first injection. "The volunteers who had been injected twice with 600 people," he said.

    Team Leader Kusnandi Rusmil said they will report the results of clinical trial research for the Covid-19 Sinovac vaccine to the first 540 volunteers in December 2020. The report would be submitted to Bio Farma as the sponsor as well as other related parties. The full research report is scheduled to be publicized in March 2021.

    ANWAR SISWADI (CONTRIBUTOR)